Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form

被引:252
作者
Skolarus, Ted A.
Dunn, Rodney L.
Sanda, Martin G.
Chang, Peter
Greenfield, Thomas K.
Litwin, Mark S.
Wei, John T.
机构
[1] Univ Michigan, Dow Div Hlth Serv Res, Dept Urol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Div Oncol, Ann Arbor, MI 48109 USA
[3] VA Ann Arbor Healthcare Syst, VA HSR&D Ctr Clin Management Res, Ann Arbor, MI USA
[4] Emory Univ, Dept Urol, Atlanta, GA 30322 USA
[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Surg, Div Urol,Med Sch, Boston, MA 02215 USA
[6] Inst Publ Hlth, Alcohol Res Grp, Emeryville, CA USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Fielding Sch Publ Hlth, Dept Urol, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
QUALITY-OF-LIFE; OUTCOMES; SATISFACTION; VALIDATION; INSTRUMENT; CARE;
D O I
10.1016/j.urology.2014.08.044
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26). Although its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences [MIDs]). METHODS We used distribution-and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, and vitality/hormonal) based on a prospective multi-institutional cohort of 1201 men treated for prostate cancer between 2003 and 2006 and followed up for 3 years after treatment. For the anchor-based approach, we compared within-subject and between-subject score changes for each domain to an external "anchor" measure of overall cancer treatment satisfaction. RESULTS We found the bowel and vitality/hormonal domains to have the lowest MID range (a 4-6 point change should be considered clinically relevant), whereas the sexual domain had the greatest MID values (10-12). Urinary incontinence appeared to have a greater MID range (6-9) than the urinary irritation/obstruction domain (5-7). CONCLUSION Using 2 independent approaches, we established the MIDs for each EPIC-26 domain. A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant. (C) 2015 Elsevier Inc.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 23 条
  • [1] Expanded Prostate Cancer Index Composite for Clinical Practice: Development and Validation of a Practical Health Related Quality of Life Instrument for Use in the Routine Clinical Care of Patients With Prostate Cancer
    Chang, Peter
    Szymanski, Konrad M.
    Dunn, Rodney L.
    Chipman, Jonathan J.
    Litwin, Mark S.
    Nguyen, Paul L.
    Sweeney, Christopher J.
    Cook, Robert
    Wagner, Andrew A.
    DeWolf, William C.
    Bubley, Glenn J.
    Funches, Renee
    Aronovitz, Joseph A.
    Wei, John T.
    Sanda, Martin G.
    [J]. JOURNAL OF UROLOGY, 2011, 186 (03) : 865 - 872
  • [2] Chen RC., 2014, J Natl Cancer Inst, V106
  • [3] Measuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice
    Chipman, Jonathan J.
    Sanda, Martin G.
    Dunn, Rodney L.
    Wei, John T.
    Litwin, Mark S.
    Crociani, Catrina M.
    Regan, Meredith M.
    Chang, Peter
    [J]. JOURNAL OF UROLOGY, 2014, 191 (03) : 638 - 645
  • [4] Active surveillance for early-stage prostate cancer - Review of the current literature
    Dall'Era, Marc A.
    Cooperberg, Matthew R.
    Chan, June M.
    Davies, Benjamin J.
    Albertsen, Peter C.
    Klotz, Laurence H.
    Warlick, Christopher A.
    Holmberg, Lars
    Bailey, Donald E., Jr.
    Wallace, Meredith E.
    Kantoff, Philip W.
    Carroll, Peter R.
    [J]. CANCER, 2008, 112 (08) : 1650 - 1659
  • [5] Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study
    Darwish-Yassine, May
    Berenji, Manijeh
    Wing, Diane
    Copeland, Glenn
    Demers, Raymond Y.
    Garlinghouse, Carol
    Fagerlin, Angela
    Newth, Gail E.
    Northouse, Laurel
    Holmes-Rovner, Margaret
    Rovner, David
    Sims, Jerry
    Wei, John T.
    [J]. JOURNAL OF CANCER SURVIVORSHIP, 2014, 8 (01) : 121 - 130
  • [6] A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
    Eton, DT
    Cella, D
    Yost, KJ
    Yount, SE
    Peterman, AH
    Neuberg, DS
    Sledge, GW
    Wood, WC
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (09) : 898 - 910
  • [7] Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer
    Gore, John L.
    Kwan, Lorna
    Lee, Steve P.
    Reiter, Robert E.
    Litwin, Mark S.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (12) : 888 - 892
  • [8] Greenfield TK., 2004, The use of psychological testing for treatment planning and outcomes assessment: Vol.3: Instruments for adults, P813
  • [9] Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy
    Hedgepeth, Ryan C.
    Labo, Jessica
    Zhang, LingLing
    Wood, David P., Jr.
    [J]. JOURNAL OF UROLOGY, 2009, 182 (01) : 221 - 227
  • [10] Comparative Effectiveness of External-Beam Radiation Approaches for Prostate Cancer
    Jacobs, Bruce L.
    Zhang, Yun
    Skolarus, Ted A.
    Wei, John T.
    Montie, James E.
    Miller, David C.
    Hollenbeck, Brent K.
    [J]. EUROPEAN UROLOGY, 2014, 65 (01) : 162 - 168